Need professional-grade analysis? Visit stockanalysis.com
$11.89B
63.81
748
6.96%
Hualan Biological Bacterin Inc. (301207) trades on SHE in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY19.38, down 2.66% from the previous close.
Over the past year, 301207 has traded between a low of CNY14.90 and a high of CNY26.05. The stock has gained 27.6% over this period. It is currently 25.6% below its 52-week high.
Hualan Biological Bacterin Inc. has a market capitalization of $11.89B, with a price-to-earnings ratio of 63.81 and a dividend yield of 6.96%.
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company's main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines. In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.
Side-by-side comparison against top Healthcare peers.